Adamis Pharmaceuticals Resubmits Zimhi New Drug Application to FDA

SAN DIEGO, May 18, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the resubmission of the Company’s New Drug Application (“NDA”) to the U.S. Food and Drug Administration...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news